# Phase II Study of Ilorasertib (ABT348) in Patients With CDKN2A Deficient Solid Tumors

> **NCT02478320** · PHASE2 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 12 (actual)

## Conditions studied

- Advanced Cancers

## Interventions

- **DRUG:** Ilorasertib

## Key facts

- **NCT ID:** NCT02478320
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-08-05
- **Primary completion:** 2022-05-12
- **Final completion:** 2022-05-12
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** Study terminated due to company's decision to discontinue drug development
- **Last updated:** 2023-07-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02478320

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02478320, "Phase II Study of Ilorasertib (ABT348) in Patients With CDKN2A Deficient Solid Tumors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02478320. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*